Search Results

• Craniopharyngioma - Identifying Bio Targets for Medical Therapy

  Advancing Treatment for Pediatric Craniopharyngioma: Prospective Pilot Study Identifying Clinically Relevant Biological Targets for Medical Therapy

• Vivistim Registry for Paired VNS Therapy (GRASP)

  Vivistim Registry for Paired VNS Therapy (GRASP)/(Bayfront)

• PILOT STUDY: CAN BRUSHING FOR CYTOKINES BE USED AS A MARKER FOR INTESTINAL INFLAMMATION IN CELIAC DISEASE?

  PILOT STUDY: CAN BRUSHING FOR CYTOKINES BE USED AS A MARKER FOR INTESTINAL INFLAMMATION IN CELIAC DISEASE?

• Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma

  Phase II Trial of Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma

• Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma

  A Phase II study of Naxitamab added to induction Therapy for Subjects with Newly Diagnosed High Risk Neuroblastoma

• Valbenazine for the Treatment of Dyskinesia Due to Cerebral Palsy

  A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Dyskinesia Due to Cerebral Palsy

• Left Atrial Appendage Exclusion for Prophylactic Stroke Reduction Trial

  Left Atrial Appendage Exclusion for Prophylactic Stroke Reduction Trial

• A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/​or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

  AAML1831 - A phase 3 randomized trial for patients with de novo AML comparing standard therapy including gemtuzumab ozogamicin GO to CPX-351 with GO, and the addition of the FLT3 inhibitor gilteritinib for patients with FLT3 mutations

• DFMO as Maintenance Therapy for Molecular High/Very High Risk and Relapsed Medulloblastoma

  Phase II Trial of Eflornithine/DFMO as Maintenance Therapy for Molecular High Risk/Very High Risk and Relapsed/Refractory Medulloblastoma

• Investigation Drug Study to Assess the Efficacy and Safety of NEXIUM for Treating Erosive Esophagitis

  A Phase III Study to Assess the Efficacy and Safety of NEXIUM for Maintenance of Healing of Erosive Esophagitis in Pediatric Patients 1 to 11 Years